SARS-Cov-2 Infection in Postmenopausal Women. New Data on Menopause Hormone Therapy

Laura Baquedano (lbaquedanome@hotmail.com)  
Miguel Servet University Hospital

Javier Navarro  
Miguel Servet University Hospital

Yasmina José  
Miguel Servet University Hospital

Alexander Tristancho  
Miguel Servet University Hospital

Ana Ruiz  
Miguel Servet University Hospital

Patricia Rubio  
Miguel Servet University Hospital

Marta Lamarca  
Miguel Servet University Hospital

Research Article

Keywords: SARS-CoV-2, COVID-19, menopause, menopause hormone therapy, isolation

Posted Date: January 14th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1157428/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objective

To address the factors involved in hospital admission and medical follow up in postmenopausal women with COVID-19 diagnosis.

Methods

Retrospective observational study. Postmenopausal women aged between 40-70 years since September 2020 until June 2021 with COVID-19 diagnosis were included. Of the 300 women cohort, 50 were receiving menopause hormone therapy (MHT)

Results

288 patients were analyzed. The mean age was 56.20 years (+/-6.06y SD). Age (p=0.030), High blood pressure (HBP) (p=0.002), respiratory disorders (p=0.003), depression (p=0.028) and fibromyalgia (p=0.030) were associated with a greater risk for hospital admission, while MHT was found as a protective factor (p=0.042). Being a health professional (p<0.001), HBP (p=0.029), respiratory disorders (p=0.022), vitamin D deficiency (p=0.010), depression (p=0.005) and fibromyalgia (p=0.001) were related with a longer follow up while MHT was related with a shorter one (p=0.010). Regression analysis showed that HBP and respiratory disorders acted as independent factors for hospital admission while MHT and fibromyalgia were for the length of follow up.

Conclusions

MHT has a positive impact in postmenopausal women with SARS-CoV-2 infection. HBP and respiratory disorders are associated with a higher risk of hospital admission of these patients.

Background

Regardless of their age, postmenopausal women tend to have a more torpid evolution of SARS-CoV-2 /COVID-19, with a higher tendency to develop serious respiratory symptoms and greater mortality (1,2). This could be explained in part, due to an important role of estradiol in immunomodulation, as it helps in the regulation of several cytokines expression and the renin angiotensin aldosterone system (3). In addition, it acts as a vasodilator and exhibit endothelium protective properties by triggering the production of nitric oxide, counteracting the vasoconstriction evoked by the inflammatory response during SARS-CoV-2 infection (4).

Several observational studies have focused on the differences in gender observed during the evolution of COVID-19 and the relationship of disease severity and mortality and estrogen exposure in women. (1,2,5,6). However, other major aspects of the infection have not been yet properly assessed. One of the hallmarks of COVID-19, is the mandatory sociosanitary quarantine that is required for patients after diagnosis to avoid further dissemination of the virus. In Spain, by order of the Ministry of Health, people are urged to remain in individual rooms or in places that allows them to maintain a two meters distance from others and seek remote health assistance (telemedicine) whenever they present with compatible symptoms (7). This highly restrictive measurements involve major limitations in family and professional areas, as well as notable negative financial and personal consequences.

The objective of this study is to assess the factors related with hospital admission and health care follow up (including home isolation follow up) following COVID-19 diagnosis in postmenopausal women.

Methods

Retrospective observational study that included 300 postmenopausal patients between 40-70 years old with SARS-CoV-2 infection proven by PCR (polymerase chain reaction) from September 2020 until June 2021 diagnosed at Miguel Servet University Hospital of Zaragoza, in Spain. Pre or perimenopausal women, non-PCR diagnoses, reinfected and vaccinated women were excluded. Of the initial 300 women, twelve were excluded due to unavailability of all clinical records.

Samples used in diagnosis, were nasopharyngeal swabs with or without oropharyngeal swabbing, taken by a trained health care professional and analyzed in the Clinical Microbiology laboratory. Patient sample was obtained using a simple randomization model using the patient database of the Gynecology department of the Hospital, collecting 30 patients each month to avoid bias generated by differences in treatment or circulating variant.

Demographic and health related data were collected form the electronic clinical record. Women working in hospitals, primary care facilities and nursing homes were classified as health care professionals. Menopause was defined retrospectively as the cessation of spontaneous...
menstruation for 12 months following STRAW criteria (8). Menopause hormone therapy (MHT) group included those whose started the treatment at least one month before COVID-19 diagnosis and did not suspend it during the infection. All types MHT were included (transdermic, oral, combined progestogens and estrogens, estrogens alone or tibolone). As respiratory disorders, chronic pathologies diagnosed before COVID-19 were included (asthma, chronic bronchitis, chronic obstructive pulmonary disease). Low vitamin D values were defined as a serum concentration below 30ng/ml.

The primary outcomes of the study were hospital admission and follow up length. Hospital admission was ordered by the emergency department physician following current hospital guidelines (9) which included chest X-ray abnormalities, oxygen saturation <93%, respiratory rate >30 breaths per minute, inadequate oral intake, or immunosuppression.

Health care follow up was performed by a primary care physician by telephone consultation following current Spanish Ministry of Health regulations. Sociosanitary isolation was always indicated since first symptoms, until the 10th day if the patient remained asymptomatic for three consecutive days. In asymptomatic cases, isolation began with the PCR result until the 10th day of infection. The attending physician kept a stablished form, specifying the end of follow up. For those patients in working age, medical follow up period, corresponded with medical sick leave, including the isolation period. A negative PCR test was required for medical discharge, with the exception of health care workers. If the patient was not working at the time, medical follow up period consisted of at least the isolation period and until clinical resolution.

This study was carried out with the approval of the Aragón Ethical committee (C.P. - C.I. PI21/277). Being a retrospective study and taking into account the anonymization process, no written informed consent was required. An informative document of the study was sent to all participants by conventional mail. Patients could request to withdraw from the study at any time. The research was conducted in accordance with Good Clinical Practice standards and the current revision of the Declaration of Helsinki.

Statistics Analysis

Discrete variables are expressed in frequencies and percentages. The parametric distribution of the quantitative variables was studied with the Kolmogorov-Smirnov test. The variables that did not follow a normal distribution were expressed with the median and interquartile range (IQR) and those that presented a normal distribution were expressed in mean and standard deviation (SD). U Mann-Whitney test was used for the analysis of dichotomous qualitative nonparametric variables, and Kruskal-Wallis test for non-dichotomous qualitative ones. A binary logistic backward stepwise regression analysis was performed for identify the independent variables related to the hospital admission indication (yes/no). Backward stepwise multiple linear regression analysis was carried out to identify the independent variables related to days of isolation. Only variables with p-value <0.05 in the univariate analysis were used to construct the final regression model. The level of statistical significance was set at p< 0.05. The data were collected and codified using IBM Statistics Process Social Sciences 22.0 for Windows (Copyright SPSS Inc., 2013) for subsequent statistical analysis.

Results

Mean age of participants was 56.2 years (+/-6.06SD). Fifty patients were receiving MHT treatment. Clinical, demographical and comorbidity characteristics of the participants are summarized in Table 1.
Table 1
Baseline data of women in the sample

|                                      | n    | %    |
|--------------------------------------|------|------|
| Age                                  |      |      |
| <60 years                            | 197  | 68,4%|
| ≥ 60 years                           | 91   | 31,6%|
| Health professional                  |      |      |
| No                                   | 232  | 81,4%|
| Yes                                  | 53   | 18,6%|
| Country of origin                    |      |      |
| Spain                                | 243  | 84,4%|
| Latin America                        | 27   | 9,4% |
| Europe                               | 14   | 4,9% |
| Sub-Saharan                          | 4    | 1,4% |
| BMI*                                 |      |      |
| <30                                  | 173  | 70,0%|
| ≥ 30                                 | 74   | 30,0%|
| Smoker                               |      |      |
| No                                   | 250  | 87,7%|
| Yes                                  | 35   | 12,3%|
| Diabetes                             |      |      |
| No                                   | 265  | 92,0%|
| Yes                                  | 23   | 8,0% |
| HBP§                                 |      |      |
| No                                   | 210  | 73,2%|
| Yes                                  | 77   | 26,8%|
| Autoimmune diseases                  |      |      |
| No                                   | 247  | 85,8%|
| Yes                                  | 41   | 14,2%|
| Immunosuppressants                   |      |      |
| No                                   | 276  | 96,5%|
| Yes                                  | 10   | 3,5% |
| Oncological history                  |      |      |
| No                                   | 269  | 93,4%|
| Yes                                  | 19   | 6,6% |
| Respiratory pathology                |      |      |
| No                                   | 259  | 89,9%|
| Yes                                  | 29   | 10,1%|
| Vit D deficiency                     |      |      |
| No                                   | 229  | 79,5%|
| Yes                                  | 59   | 20,5%|
| Depression                           |      |      |
| No                                   | 217  | 75,3%|
| Yes                                  | 71   | 24,7%|
| Fibromyalgia                         |      |      |
| No                                   | 276  | 95,8%|
| Yes                                  | 12   | 4,2% |
| Years from menopause                 |      |      |
| 0-4                                  | 95   | 35,3%|
| ≥ 5                                  | 174  | 64,7%|
| MHT^                                 |      |      |
| No                                   | 238  | 82,6%|

*BMI: body mass index

§ HBP: high blood pressure

^ MHT: Menopause hormone therapy
Table 2 shows the statistical analysis of clinical characteristics, demographics and use of MHT compared with hospital admission. Older age (14.7% <60y vs 25.3% >60y, OR 1.959, 95% CI 1.059-3.626, p=0.030), High Blood pressure (HBP) (28.6% vs 14.3%, OR 2.596, 95% CI 1.389-4.849, p=0.002), respiratory disorders (57.9% vs. 15.8%, OR 3.249, 95% CI 1.430-7.385, p=0.003), depression (26.8% vs. 15.2%, OR 2.037, 95% CI 1.071-3.875, p=0.028) and fibromyalgia (41.7% vs. 17.1%, OR 3.480, 95% CI 1.059-11.437, p = 0.030) appeared to be a risk factor for hospital admission with statistical significance. On the contrary, MHT was linked with a lower risk for hospital admission (8% vs. 20.2%, OR 0.334, 95% CI 0.118-1.003, p=0.042). Other variables included showed no significant association with hospital admission.
| Table 2  
Factors related to hospital admission for COVID-19 |
|------------------------------------------------|
| Hospital admission for COVID-19 | No | Yes | p value | OR IC95% |
| Age | <60 years | 168 (85.3) | 29 (14.7) | 0.030 | 1.959 (1.059-3.626) |
| | ≥ 60 years | 68 (74.7) | 23 (25.3) |  |  |
| Health professional | No | 190 (81.9) | 42 (18.1) | 0.897 | 1.052 (0.490-2.261) |
| | Yes | 43 (81.1) | 10 (18.9) |  |  |
| Country of origin | Spain | 203 (83.5) | 40 (16.5) | 0.176 | - |
| | Latin America | 18 (66.7) | 9 (33.3) |  |  |
| | Europe | 12 (85.7) | 2 (14.3) |  |  |
| | Sub-Saharan | 3 (75) | 1 (25) |  |  |
| BMI* | <30 | 142 (82.1) | 31 (17.9) | 0.497 | 1.264 (0.643-2.485) |
| | ≥ 30 | 58 (78.4) | 16 (21.6) |  |  |
| Smoker | No | 202 (80.8) | 48 (18.2) | 0.265 | 0.543 (0.183-1.612) |
| | Yes | 31 (88.5) | 4 (11.4) |  |  |
| Diabetes | No | 220 (83) | 45 (17) | 0.108 | 2.139 (0.832-5.499) |
| | Yes | 16 (69.6) | 7 (30.4) | |  |
| HBP§ | No | 180 (85.7) | 30 (14.3) | 0.002 | 2.596 (1.389-4.849) |
| | Yes | 55 (71.4) | 22 (28.6) |  |  |
| Autoimmune diseases | No | 202 (81.7) | 45 (18.3) | 0.860 | 0.924 (0.385-2.218) |
| | Yes | 34 (82.9) | 7 (17.1) |  |  |
| Immunosuppressants | No | 226 (81.8) | 50 (18.1) | 0.510 | 0.502 (0.062-4.055) |
| | Yes | 9 (90) | 1 (10) |  |  |
| Oncological history | No | 220 (81.8) | 49 (18.2) | 0.790 | 0.842 (0.236-3.002) |
| | Yes | 16 (84.2) | 3 (15.8) |  |  |
| Respiratory pathology | No | 218 (84.2) | 41 (15.8) | 0.003 | 3.249 (1.430-7.385) |
| | Yes | 18 (62.1) | 11 (57.9) |  |  |
| Vit D deficiency | No | 191 (83.4) | 38 (16.6) | 0.204 | 1.564 (0.782-3.129) |
| | Yes | 45 (76.3) | 14 (23.7) |  |  |
| Depression | No | 184 (84.8) | 33 (15.2) | 0.028 | 2.037 (1.071-3.875) |
| | Yes | 52 (73.2) | 19 (26.8) |  |  |
| Fibromyalgia | No | 229 (82.9) | 47 (17.1) | 0.030 | 3.480 (1.059-11.437) |

*BMI: body mass index  
§ HBP: high blood pressure  
^ MHT: Menopause hormone therapy
|                          | Yes | 7 (58.3) | 5 (41.7) | Years from menopause | 0-4 | 77 (81.1) | 18 (18.9) | 0.997 | 1.001 (0.529-1.895) | ≥ 5 | 141 (81) | 33 (19) |
|--------------------------|-----|----------|----------|----------------------|-----|-----------|-----------|-------|---------------------|-----|-----------|---------|
| MHT^                     | No  | 190 (79.8) | 48 (20.2) | 0.042 | 0.344 (0.118-1.003) | Yes | 46 (92) | 4 (8) |

*BMI: body mass index

‡ HBP: high blood pressure

^ MHT: Menopause hormone therapy

Table 3 summarizes the relationship between studied factors and length of follow up. Working in a healthcare facility (p<0.001), HBP (p=0.029), chronic respiratory conditions (p=0.022), low levels of serum Vitamin D (p=0.010), depression (p=0.005) and fibromyalgia (p=0.001) were related with a prolonged follow up period. MHT was related with a decrease in follow up length (p=0.010).
|                              | Medical follow up for covid | p value |
|------------------------------|----------------------------|---------|
|                              | Mediana (ICR)              |         |
| Age                          |                            |         |
| <60 years                    | 16 (314)                   | 0.152   |
| ≥ 60 years                   | 20 (148)                   |         |
| Health professional          |                            |         |
| No                           | 15 (314)                   | <0.001  |
| Yes                          | 22 (127)                   |         |
| Country of origin            |                            |         |
| Spain                        | 17 (314)                   | 0.818   |
| Latin America                | 18 (132)                   |         |
| Europe                       | 16 (50)                    |         |
| Sub-Saharan                  | 12 (49)                    |         |
| BMI*                         |                            |         |
| <30                          | 17 (314)                   | 0.820   |
| ≥ 30                         | 16 (136)                   |         |
| Smoker                       |                            |         |
| No                           | 17 (314)                   | 0.244   |
| Yes                          | 15 (71)                    |         |
| Diabetes                     |                            |         |
| No                           | 17 (314)                   | 0.586   |
| Yes                          | 15 (129)                   |         |
| HBP$                         |                            |         |
| No                           | 16 (314)                   | 0.029   |
| Yes                          | 21 (149)                   |         |
| Autoimmune diseases          |                            |         |
| No                           | 17 (314)                   | 0.125   |
| Yes                          | 20 (116)                   |         |
| Immunosuppressants           |                            |         |
| No                           | 17 (314)                   | 0.991   |
| Yes                          | 19 (59)                    |         |
| Oncological history          |                            |         |
| No                           | 17 (314)                   | 0.210   |
| Yes                          | 18 (57)                    |         |
| Respiratory pathology        |                            |         |
| No                           | 17 (314)                   | 0.022   |
| Yes                          | 21 (136)                   |         |
| Vit D deficiency             |                            |         |
| No                           | 16 (314)                   | 0.010   |
| Yes                          | 18 (71)                    |         |
| Depression                   |                            |         |
| No                           | 24 (16)                    | 0.005   |
| Yes                          | 28 (21)                    |         |
| Fibromyalgia                 |                            |         |
| No                           | 17 (314)                   | 0.001   |
| Yes                          | 40 (145)                   |         |
| Years from menopause         |                            |         |
| 0-4                          | 15 (313)                   | 0.221   |
| ≥ 5                          | 17 (149)                   |         |

*BMI: body mass index

$HBP$: high blood pressure

^MHT: Menopause hormone therapy
Binary logistic regression analysis revealed HBP and chronic respiratory conditions were identified as independent factors for hospital admission. No other factors were found to be independently related in the binary logistic regression (Table 4).

### Table 4

Results of the binary logistic regression analysis of the factors related to hospital admission for COVID-19. Only variables with $p < 0.05$ are included in the univariate analysis.

|                  | $\beta$ coefficient | Standard error | Wald  | Exp(B) | 95% Confidence interval | p value |
|------------------|---------------------|----------------|-------|--------|-------------------------|---------|
| Age              | 0.466               | 0.334          | 1.944 | 1.594  | 0.828                   | 3.07    |
| HBP$^*$           | 0.745               | 0.330          | 5.089 | 2.107  | 1.103                   | 4.026   |
| Respiratory pathology | 1.061          | 0.443          | 5.747 | 2.88   | 1.214                   | 6.88    |
| Depression       | 0.456               | 0.348          | 1.714 | 1.577  | 0.797                   | 3.119   |
| Fibromyalgia     | 0.915               | 0.637          | 2.064 | 2.497  | 0.717                   | 8.7     |
| MHT$^*$          | -0.9                | 0.576          | 2.444 | 0.355  | 0.118                   | 1.069   |

$^*$ HBP: high blood pressure

$^*$ MHT: Menopause hormone therapy

Multiple linear regression analysis established fibromyalgia and MHT as independent factors for longer and shorter follow up periods respectively (Table 5).

### Table 5

Results of the linear logistic regression analysis of the factors related to medical follow up for COVID-19. Only variables with $p < 0.05$ are included in the univariate analysis.

|                  | $\beta$ coefficient | Error desviation | $\beta$ coefficient | t       | 95% Confidence interval | p value |
|------------------|---------------------|------------------|---------------------|---------|-------------------------|---------|
| Health professional | 0.092               | 4.379            | 0.092               | 1.587   | -1.672                  | 15.569  |
| HBP$^*$           | 0.07                | 3.989            | 0.07                | 1.155   | -3.247                  | 12.458  |
| Respiratory pathology | 0.083          | 5.76             | 0.083               | 1.392   | -3.324                  | 19.354  |
| Depression       | 0.009               | 4.04             | 0.009               | 0.152   | -7.338                  | 8.568   |
| Vit D deficency  | -0.02               | 4.301            | -0.02               | -0.334  | -9.904                  | 7.028   |
| Fibromyalgia     | 0.216               | 8.724            | 0.216               | 3.754   | 15.579                  | 49.925  |
| MHT$^*$          | -0.116              | 4.464            | -0.116              | -2.019  | -17.8                   | -0.225  |

$^*$ HBP: high blood pressure

$^*$ MHT: Menopause hormone therapy

**Discussion**

The main highlight of our study is that MHT in postmenopausal women seems to be related with a quicker recovery from COVID-19, proved by a lower rate of hospital admission and a shorter follow up length. To our best knowledge, this is the first study that evaluates MHT and COVID-19 related aspects. HBP and respiratory disorders were related as independent factors for greater risk of hospital admission due to
COVID-19. MHT was linked with a fewer rate of hospital admission; although was not found as an independent factor in the multivariate analysis.

Epidemiological studies in the general population have focused in factors associated with a poor clinical outcome of COVID-19 (10, 11). In a systematic review including 207 studies and more than 75,000 patients from twelve countries, in consistency with our data, found that factors as age, HBP, and chronic respiratory conditions were related with higher disease severity and worst clinical outcome of COVID-19 (12). Epidemiological studies usually do not consider factors as depression or fibromyalgia, even when those are highly prevalent among postmenopausal women, making them a relevant target to correlate with disease progression (13–15). According to our results, both fibromyalgia and depression are related with a more severe infection and extended follow up, although only fibromyalgia proved to be an independent factor for domiciliary isolation. Taking that into account, we strongly believe that those are important factors to be included and evaluated in postmenopausal women with COVID-19.

Several studies have shown greater disease severity in men compared with women, pointing to a possible protective role of estrogens. (2, 5, 16–18). Even between pre and postmenopausal women, there are differences in prognosis regardless of age. (19). Seeland et al, in a wide epidemiological study found that postmenopausal women above 50 years old under MHT with COVID-19, had a reduction greater than 50% in mortality, driven by estrogens levels (1). Recently, another important epidemiological study using the COVID Symptom Study Smartphone Application in the United Kingdom, including around 18,000 women with COVID-19 under MHT, found that hospital admission was not greater in this group of patients, although they exhibit a higher and broader spectrum of symptoms. Only age, mass body index and smoking habit were assessed as confounding variables, nevertheless, diagnosis was made based on symptoms and prediction models and not in molecular tests, which potentially limits extrapolation of results (20).

Medical sick leave and domiciliary isolation, have deleterious implications at the social, family and working levels, without mentioning at the economical sphere. The deleterious cognitive and emotional consequences of this highly restrictive measurement, due to the physical distancing from the usual environment and dimensions in which patients have to reside during days or weeks, has been studied (21). Besides, working cessation in women who work as independents, posed great drawbacks in income (22). Lastly, it has been noted that prolonged domiciliary isolation has a negative impact in quality of life related to menopause, measured with specific quality of life instruments for menopause (23).

Because of everything mentioned above, a prompt recovery and a shorter isolation period is crucial to the wellbeing of menopausal women in all means. In our study, postmenopausal women under MHT finished their isolation and returned to daily life faster. It is possible that estrogens as a protective factor played an important role in this scenario, especially in the early stages of the infection. In addition, alleviation of climacteric symptoms by MHT could also improve patient wellbeing and avoid COVID-19 symptoms masking. For this reason, unlike some recommendations given in the early phases of the coronavirus pandemic, it does not seem reasonable to suspend MHT in symptomatic postmenopausal women with non-serious infection (24).

We believe that these results will contribute to the scaring literature regarding the management of postmenopausal COVID-19 patients and could be used as a reference for future research involved in the establishment of the the relationship between exogenous estrogens intake and viral infections outcomes. Nevertheless, the results of this work should be taken cautiously, as we are aware of the several limitations of this study. Limited number of patients presented, especially in the MHT group, impossibility to perform a comparison regarding administration route, composition or doses of MHT and a potentially source of bias arising from the analysis based on their employment status. This last one is minimized given the fact that the health care professional in charge of the follow up, was required to specify the end of follow up in an epidemiological survey.

**Conclusions**

MHT can positively influence the evolution of coronavirus infection in postmenopausal women. HBP and respiratory diseases are associated with a higher rate of hospital admission in postmenopausal women with SARS-CoV-2 infection.

**Abbreviations**

MHT: menopause hormone therapy

PCR: polymerase chain reaction

HBP: High Blood pressure

BMI: body mass index
Declarations

Ethics approval and consent to participate

This study was carried out with the approval of the Aragón Ethical committee (C.P. - C.I. PI21/277). Being a retrospective study and considering the anonymization process, no written informed consent was required. An informative document of the study was sent to all participants by conventional mail. Patients could request to withdraw from the study at any time.

Availability of data and materials

The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Competing interests

The authors declare no conflict of interest.

Funding

There was no financial support, participant compensation, or funding for the research team.

Authors' contributions

LB: is one of the study designers, has participated in the elaboration and writing of the article and is the current corresponding author. JN: has carried out data collection and critical revision of the manuscript. YJ: has carried out data collection and analysis and manuscript writing. AT: has carried out data collection and analysis and manuscript writing. PR: has carried out data collection and analysis. AR: has carried out data collection and critical revision of the manuscript. ML: is one of the study designers, has participated on writing of the manuscript and critical revision of it.

Acknowledgments

To the clinical microbiology laboratory to help in the procurement of COVID-19 diagnosed patients.

References

1. Seeland U, Coluzzi F, Simmaco M, et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020 Nov 25;18(1):369.
2. Wang XW, Hu H, Xu ZY, et al. Association of menopausal status with COVID-19 outcomes: a propensity score matching analysis. Biol Sex Differ. 2021 Jan 29;12(1):16.
3. Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279.
4. Hishikawa K, Nakaki T, Marumo T, et al. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 1995;360(3):291–293.
5. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81.
6. Jin, J. M., Bai, P., He, W., Wu, F., Liu, X. F., Han, D. M., et al. (2020). Gender differences in patients with COVID-19: focus on severity and mortality. Front. Public Health 8:152.
7. Ministry of Spanish Health, Consumption and Social Welfare (internet). Coronavirus disease, COVID-19. Technical documents for professionals. Recommendations for the management of clinical cases. Management of COVID-19 in primary and home care. 06.18.2020. Available from https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Manejo_primaria.pdf.
8. S.D. Harlow, M. Gass, J.E. Hall, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging, J Clin Endocrinol Metab. 2012 Apr;97(4):1159–68.
9. Ministry of Spanish Health, Consumption and Social Welfare (internet). Coronavirus disease, COVID-19. Technical documents for professionals. Recommendations for the management of clinical cases. Clinical management of COVID-19: hospital care 06.18.2020. Available from https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/Protocolo_manejo_clinico_ah_COVID-19.pdf

10. Shi C, Wang L, Ye J, et al. Predictors of mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis. BMC Infect Dis. 2021 Jul 8;21(1):663.

11. Lacedonia D, Scioscia G, Santomasi C, et al. Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients. Sci Rep. 2021 Sep 28;11(1):19251.

12. Izcovich A, Ragusa MA, Tortosa F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One. 2020;15(11):e0241955.

13. Bazzichi L, Giacomelli C, Rossi A, et al. Fibromyalgia and sexual problems. Reumatismo. 2012; 64(4), 261–7.

14. Romero-Alcalá P, Hernández-Padilla JM, Fernández-Sola C, et al. Sexuality in male partners of women with fibromyalgia syndrome: A qualitative study. PLoS One. 2019;14(11):e0224990.

15. Clayton AH, Ninan PT. Depression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women. Prim Care Companion J Clin Psychiatry. 2010;12(1):PCC.08r00747.

16. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20

17. Bienvenu LA, Noonan J, Wang X, et al. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res. 2020 Dec 1;116(14):2197-2206

18. Lee JH, Kim VC, Cho SH, Lee J, You SC, Song YG, Won YB, Choi YS, Park YS. Effect of sex hormones on coronavirus disease 2019: an analysis of 5,061 laboratory-confirmed cases in South Korea. Menopause. 2020 Dec;27(12):1376–1381

19. Mishra N, Sharma R, Mishra R, et al. COVID-19 and Menstrual Status: Is Menopause an Independent Risk Factor for SARS Cov-2? J Midlife Health. 2020 Oct-Dec;11(4):240–249

20. Costeira R, Lee KA, Murray B, et al. Estrogen and COVID-19 symptoms: Associations in women from the COVID Symptom Study. PLoS One. 2021 Sep 10;16(9):e0257051

21. Bland AR, Roiser JP, Mehta MA, et al. The impact of COVID-19 social isolation on aspects of emotional and social cognition. Cogn Emot. 2021 Feb 25:1–10.

22. Hafez HM, Attia YA, Bovera F, et al. Influence of COVID-19 on the poultry production and environment. Environ Sci Pollut Res Int. 2021 Sep;28(33):44833–44844.

23. Coronado PJ, Fasero M, Otero B, et al. Health-related quality of life and resilience in peri- and postmenopausal women during Covid-19 confinement. Maturitas. 2021 Feb;144:4–10

24. Ramírez I, De la Viuda E, Baquedano L, et al. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecologia y Obstetricia and Sociedad Española de Trombosis y Hemostasia. Maturitas. 2020 Jul;137:57-62